The BRAF gene plays a crucial role in controlling how cells grow and divide in our bodies. When mutations occur in this gene, cells can grow uncontrollably, potentially leading to various types of cancer. Understanding BRAF gene mutations has become increasingly important in modern medicine, as these changes affect treatment choices and outcomes for many cancer patients.
What Is the BRAF Gene and How Does It Work?
The BRAF gene provides instructions for making a protein that acts like a messenger inside our cells. This protein is part of a communication pathway known as the RAS/MAPK pathway, which is essentially a chain of signals that tells cells when to grow, divide, mature, move, or even self-destruct. Think of it as a control system that keeps cell behavior in check, ensuring that cells only grow and divide when needed.[1]
This signaling pathway is essential for normal development before birth and continues to play a vital role throughout life. The BRAF protein specifically helps transmit chemical signals from outside the cell to its nucleus, where important decisions about cell behavior are made. When everything works properly, this system maintains a careful balance that keeps our tissues healthy and functioning normally.[1]
The BRAF gene belongs to a class of genes called oncogenes. While this term sounds alarming, it simply means that when these genes undergo mutations, they have the potential to cause normal cells to become cancerous. In their normal, unmutated state, oncogenes perform important functions in regulating cell growth and division.[1]
How Common Are BRAF Mutations?
BRAF mutations occur at different rates depending on the type of cancer. In colorectal cancer, approximately 10 to 15 percent of cases involve BRAF mutations. These mutations are more common in tumors located in the right side of the colon compared to those on the left side or in the rectum.[3][7]
Melanoma, a serious type of skin cancer, shows a much higher rate of BRAF mutations. About 35 percent of melanomas carry these genetic changes, and in some studies, estimates suggest that approximately 50 percent of people with advanced melanoma have BRAF V600 mutations.[3][8]
In lung cancer, specifically non-small cell lung cancer, BRAF mutations are relatively rare. They occur in about 3 to 5 percent of all cases and are found almost exclusively in a subtype called adenocarcinoma, which starts in the outer areas of the lungs.[10][11]
Thyroid cancer shows notably high rates of BRAF mutations, with more than 50 percent of thyroid papillary carcinomas carrying these genetic changes. This makes BRAF mutations particularly relevant for understanding and treating certain thyroid cancers.[3]
Understanding BRAF Mutations
The most common BRAF mutation is called V600E, which is classified as a class I mutation. This designation refers to a specific change in the gene where the amino acid valine at position 600 is replaced by glutamic acid. In simpler terms, a single building block in the protein’s structure is swapped for a different one, fundamentally changing how the protein behaves.[1][3]
The V600E mutation causes the BRAF protein to become abnormally active all the time. Instead of only sending signals when appropriate, the mutated protein continuously tells cells to grow and divide, regardless of whether the body needs new cells. This uncontrolled signaling disrupts the carefully regulated RAS/MAPK pathway throughout the body, interfering with normal development and function of many organs and tissues.[1]
While V600E is the most common mutation, BRAF mutations are now classified into three different classes based on their biological characteristics. Class I mutations include V600E and behave in a specific way. Classes II and III, which are non-V600 mutations, work differently and have different implications for treatment. This classification system helps doctors predict how well certain therapies might work.[2][10]
What Causes BRAF Mutations?
BRAF mutations in cancer occur as somatic mutations, which means they happen during a person’s lifetime rather than being inherited. These genetic changes develop in non-reproductive cells, appearing in cells that will become part of tissues like skin, colon, or lungs. The mutation is acquired, not present from birth.[3]
In conditions like giant congenital melanocytic nevus, the V600E mutation occurs during embryonic development in cells destined to become melanocytes, which are pigment-producing skin cells. This early mutation leads to unregulated cell proliferation, resulting in large patches of darkly pigmented skin that are present from birth. Additional mutations occurring after birth in cells within these patches can lead to melanoma development.[1]
The development of BRAF mutations represents one step in cancer formation. Gene mutations can induce cellular alteration and malignant transformation, with the BRAF mutation occurring early in cancer development. Once present, the mutation signals certain cells to grow uncontrollably, contributing to tumor formation and progression.[2][7]
Risk Factors and Associated Conditions
BRAF mutations in colorectal cancer are associated with several distinct characteristics. They occur more frequently in females, people of advanced age, and tumors with specific features. The mutations are more common in tumors located in the proximal (right-sided) colon, T4 tumors (which have grown through the bowel wall), poorly differentiated cancers, and tumors with defective mismatch repair systems.[9]
Patients with BRAF mutant colorectal cancer typically face a poor prognosis and often do not respond well to standard therapy. The median survival for these patients is approximately 12 months, which is notably shorter than for patients without BRAF mutations. This difficult outlook underscores why new therapies specifically targeting BRAF mutations are needed.[9]
In melanoma, BRAF mutations are not necessarily linked to typical sun exposure patterns. Some patients with BRAF-positive melanoma report being educated about sun safety, regularly applying sunscreen, never using tanning beds, and performing regular skin checks, yet still developing melanoma with BRAF mutations. This suggests that factors beyond simple sun exposure may contribute to BRAF mutation development in melanoma.[12]
Certain inherited conditions can be caused by BRAF mutations. Cardiofaciocutaneous syndrome, which affects the heart, facial features, skin, and hair, is most commonly caused by BRAF mutations. At least 49 different BRAF mutations have been identified in people with this disorder. Noonan syndrome with multiple lentigines can also result from BRAF gene mutations.[1]
How BRAF Mutations Affect the Body
When a BRAF mutation occurs, it fundamentally changes how the protein functions. The most common V600E mutation leads to production of a BRAF protein that is abnormally active. This constant activation disrupts the regulation of cell proliferation, which is the process of cells multiplying and increasing in number.[1]
The V600E mutation causes constitutive BRAF kinase activity, meaning the enzyme is always switched on. This leads to continuous phosphorylation of MEK and ERK kinases, which are other proteins in the signaling pathway. The result is sustained MAPK pathway signaling that never turns off, constantly telling cells to grow and divide regardless of what the body needs.[9]
In giant congenital melanocytic nevus, the disrupted regulation allows early melanocytes to proliferate uncontrollably during development, creating large patches of darkly pigmented skin visible at birth. The unregulated cell growth doesn’t stop at appropriate boundaries, leading to overgrowth of pigmented cells in specific areas.[1]
In Erdheim-Chester disease, the BRAF V600E mutation affects immune system cells called histiocytes. The abnormally active BRAF protein allows these histiocytes to grow and divide uncontrollably, leading to their abnormal accumulation in various tissues throughout the body. This accumulation commonly affects bones, causing thickening and pain, but can also impact the brain, eyes, lungs, liver, kidneys, and other organs.[1]
The altered signaling in cardiofaciocutaneous syndrome interferes with normal development of many organs and tissues. Because the RAS/MAPK pathway is essential for proper development before birth, genetic changes that abnormally activate the pathway throughout the body can result in characteristic features affecting multiple body systems.[1]
Testing for BRAF Mutations
All patients with stage IV or metastatic colorectal cancer should have BRAF biomarker testing. This testing helps determine which treatments may work best for each individual patient. Testing is also important in melanoma and lung cancer cases to guide treatment decisions.[3]
The recommended method of testing uses a biopsy sample of cancer cells, which can be taken from either the primary tumor or from metastases that have spread to other parts of the body such as lymph nodes, liver, or peritoneum. In the laboratory, cancer cells are treated to isolate the tumor DNA, which is then studied for BRAF mutations.[3]
BRAF can also be tested through a blood sample by examining circulating tumor DNA (ctDNA), which is DNA shed by cancer cells into the bloodstream. This approach is called a liquid biopsy and offers a less invasive testing option. Blood tests can sometimes detect BRAF mutations without requiring a tissue biopsy.[3]
BRAF may be tested individually or as part of a multi-gene panel using next-generation sequencing (NGS), a technology that can examine many genes simultaneously. BRAF mutation testing may also be called BRAF mutation analysis or BRAF gene sequencing. The testing process is the same regardless of terminology.[3]
Test results are typically reported as either “BRAF wild-type” or “BRAF WT,” which means no BRAF mutation was found in the cancer, or as BRAF mutant positive, indicating a mutation is present. The specific type of mutation, such as V600E, is usually identified in the report. These results help doctors understand both prognosis and which treatments may be effective.[3]
Treatment Implications of BRAF Mutations
In melanoma, two main treatment approaches exist for patients with BRAF V600 mutations: targeted therapy combinations and immunotherapy combinations. A landmark study called DREAMseq compared these approaches and found important differences in outcomes. More patients treated first with the immunotherapy combination of ipilimumab and nivolumab were alive at two years compared to those treated first with targeted therapy (72 percent versus 52 percent).[8]
Targeted therapy for BRAF-mutated melanoma typically involves combining a BRAF inhibitor with a MEK inhibitor. MEK is another protein that works in conjunction with BRAF in the signaling pathway. Common combinations include dabrafenib with trametinib, which are taken as pills. These drugs specifically block the activity of mutated BRAF proteins and MEK proteins.[8]
The five-year survival rate for melanoma patients with BRAF mutations receiving combined targeted therapy reached 34 percent in treatment-naïve patients. When these same patients received first-line immune checkpoint blockade with ipilimumab plus nivolumab, the five-year survival rate was 60 percent. These immunotherapy drugs are administered intravenously and work by blocking proteins that prevent immune cells from attacking cancer.[16]
In colorectal cancer, BRAF inhibitor monotherapy has shown limited efficacy, unlike in melanoma. Combination strategies that block not only the BRAF mutated kinase but also other alternative pathways have demonstrated improved activity. Colorectal cancer with BRAF mutations can be treated with targeted therapy combining BRAF inhibitors plus MEK inhibitors.[3][9]
For lung cancer with BRAF mutations, particularly the V600E mutation, the FDA has approved certain targeted medications. Treatment approaches may differ depending on whether the mutation is V600 (class I) or non-V600 (classes II and III), as these different mutation types have distinct biological characteristics that affect therapeutic benefit.[10]
Resistance mechanisms to BRAF and MEK inhibition remain a major problem in treating patients with targeted therapies. Not all patients respond to treatment, and those who do respond may eventually develop resistance as cancer cells find ways to circumvent the blocked pathways. This ongoing challenge drives research into new combination approaches and treatment strategies.[16]
Side effects differ significantly between targeted therapies and immunotherapies. Targeted therapies specifically target tumor cells, generally causing different side effects than immunotherapies, which work by enhancing the immune system’s ability to fight cancer. A key consideration in choosing initial treatment involves weighing these different side effect profiles against potential benefits.[8]
Clinical Significance and Prognosis
BRAF mutation status provides important prognostic information. In colorectal cancer, the presence of a BRAF mutation is associated with distinct clinical and pathological features and generally indicates a poorer prognosis. Patients with BRAF mutant colorectal cancer face particular challenges, as these tumors are often more aggressive and less responsive to standard treatments.[9]
Negative predictive biomarkers can affect outcomes in BRAF-mutated cancers. Elevated lactate dehydrogenase levels, high numbers of metastatic organ disease sites, and brain metastases represent factors associated with worse outcomes. These characteristics help doctors assess individual patient prognosis and make treatment decisions.[16]
Long-term survival can be reached in melanoma patients with BRAF mutations, particularly those receiving appropriate targeted or immunotherapy. However, it remains unclear whether achieving long-term survival is equivalent to reaching a true cure for metastatic melanoma. Ongoing follow-up and research continue to clarify whether patients can be considered cured or require lifelong monitoring.[16]
Patient experiences illustrate the importance of knowing BRAF status early. For some melanoma patients, learning they were BRAF positive represented their first ray of hope, as it meant specific targeted treatments were available. Early testing allowed these patients to quickly move forward with appropriate treatment plans rather than delaying while determining the best approach.[12][13]
The discovery of BRAF mutations and development of treatments targeting these changes represents significant progress in cancer care. What was once considered a universally fatal diagnosis when cancer spread has transformed into a situation where long-term survival and potentially cure are achievable for some patients. This transformation occurred relatively recently, with many targeted therapies and immunotherapies approved only within the last decade.[8][12]
